Tag Archives: West Los Angeles neurologist
The neurological drug pregabalin (Lyrica), will soon be available in presumably lest expensive generic form. Lyrica users have reported costs ranging from about $30 a month with insurance coverage to around $134 a month without coverage.Read more
The antidepressant duloxetine (Cymbalta) relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients in a phase III study, making it the first drug to prove effective for treating the common adverse event, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting.
The findings are expected to change clinical practice, as the drug potentially offers a new way to achieve quality-of-life improvements for a large pool of patients. Peripheral neuropathy affects 20% to 30% of patients treated with taxanes and platinum-based chemotherapy, with a spectrum of severity that can affect such daily activities as walking, working, sleep patterns, and mood. Although many patients may experience manageable numbness and tingling in the hands and feet, others find peripheral neuropathy chronic and debilitating.
“This study is significant because to date there has been no study that has demonstrated that any drug works for painful chemotherapy-induced peripheral neuropathy,” lead investigator Ellen M. Lavoie Smith, PhD, assistant professor in the School of Nursing at the University of Michigan, Ann Arbor, said in an interview. She released the results at a press briefing Sunday.Read more
In a recent study, researchers at Evergreen Healthcare discovered that a new form of a commonly used drug to treat patients with Parkinson’s disease could greatly improve their quality of life and reduce their symptoms like tremors, slowness, stiffness and difficulty walking. The study, which involved 71 participants, was intended to measure the effectiveness of the standard oral dosages of a common Parkinson’s medication against its newer form, the levodopa-carbidopa intestinal gel. Lead investigator at Evergreen’s Booth Gardner Parkinson’s Care Center Dr. Alida Griffith stated, “We have been involved in the trials since 2008. Levodopa is the ‘gold standard’ treatment [...]Read more
News sources reported that a recent study published in The Journal of Pain found evidence that a lack of sleep is not a reliable predicting factor in the pain intensity and duration for fibromyalgia patients. Researchers at the University of Florida recently conducted a study to determine if lack of sleep or poor sleep quality is related to higher levels of pain intensity in patients suffering from fibromyalgia. The study followed 74 adult patients diagnosed with fibromyalgia for two weeks. The patients recorded the quality and amount of each night’s sleep in journals. Though fibromyalgia patients are known for having [...]Read more
In a recent study from the Sleep Disorders and Research Center in the Henry Ford Health System of Detroit, researchers found that the drug pregabalin provided patients suffering from fibromyalgia with significant improvements in both their sleeping habits and decreased daily pain. The study was a randomized, double blind, placebo-controlled crossover study that used polysomonographic (PSG) measures of sleep to determine results. Participants included fibromyalgia patients already in the system. The participants were given 300- to 450 mg of pregalabin every day and showed a reduction in PSG-determined awakenings versus sleep onset of 19.2 minutes versus the placebo’s 26.7 minutes. [...]Read more
Media outlets reported that a recent study from Johns Hopkins University discovered that more than a third of patients that are thought to have neurologically based seizures were really suffering from stress-triggered symptoms. Several physicians and psychologists at Johns Hopkins found that more than 33 percent of the individuals admitted to the Johns Hopkins Hospital’s inpatient epilepsy monitoring unit were displaying stress symptoms, not seizure disorders. The patients were from all walks of life and suffering from what is referred to as psychogenic non-epileptic seizures (PNES). Symptoms of PNES include uncontrollable movements and far-off stares or convulsions. The study found [...]Read more
In a recent study conducted at Northwestern Memorial Hospital, researchers sought to determine whether the recently FDA approved gel-coated coils provide a more effective treatment of endovascular brain aneurysms than the prominent bare platinum coils currently used. Bernard R. Bendok, MD, neurosurgeon at Northwestern Memorial Hospital and principal investigator for the new generation Hydrogel Endovascular Aneurysm Treatment Trial (HEAT), which is a global randomized study that will measure how bare coils compare to the new gel coils in the prevention of aneurysm recurrence, stated, “When an aneurysm needs treatment, it is important to perform the safest, most effective and most [...]Read more
In a press statement, the US Food and Drug Administration (FDA) announced the approval of Neupro, also known as the rotigotine transdermal system, for the treatment of Parkinson’s disease (PD) and Restless Legs Syndrome (RLS). The drug is designed to treat the symptoms of advanced stage idiopathic PD and moderate-to-severe primary RLS. Neupro is a dopamine agonist patch that is able to provide patients with continuous drug delivery. Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President of Global Projects and Development at the University of California, Berkeley (UCB), said, “Neupro represents an innovation in the treatment of Parkinson’s [...]Read more
A recent study uncovered that the process of recalling a memory is, on a molecular level, almost identical to the protein synthesis that occurs when forming a new memory. This indicates that memories can actually be erased while protein processes for synthesis are temporarily blocked. In the late 90s, neurologist Karim Nader at New York University realized that no one understood the process of recalling a memory. Nader said, “My big advantage was that I wasn’t trained in memory. I was very naïve about the subject.” He hypothesized that, since protein synthesis was the basis for building a memory, additional [...]Read more
A recent study conducted by researchers at the Neuropsychopharmacology Unit at Imperial College London discovered that the hallucinogen Psilocybin could have positive effects on an individual’s depressive symptoms and enhance their memory. According to lead researcher Dr. Robin L. Carhart-Harris, “Psilocybin decreases brain activity in regions such as the medial prefrontal cortex that are overactive in depression.” Carhart-Harris also stated that patients, while under the influence of Psilocybin and undergoing psychotherapy, experience “sudden personal insights.” The researchers also found the while patients were under the influence of the hallucinogen and shown personal memory cues, then asked to recall their emotions [...]Read more